Lifibrol

Summary

Lifibrol (CHEMBL2105019) is a phase-3 clinical-stage small molecule.

At a glance

• Status: Max clinical phase 3 (not approved)
• Modality: Small molecule
• Clinical trials: 1
• Chemistry: 342.4 Da · C21H26O4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2105019
Name	Lifibrol
Type	Small molecule
Max phase	3
FDA approved	no
PubChem CID	57112
Molecular formula	C21H26O4
Molecular weight	342.4
InChIKey	LNXBEIZREVRNTF-UHFFFAOYSA-N

SMILES: CC(C)(C)C1=CC=C(C=C1)CCC(COC2=CC=C(C=C2)C(=O)O)O

IUPAC name: 4-[4-(4-tert-butylphenyl)-2-hydroxybutoxy]benzoic acid

Also known as: K 12148, K-12148, Lifibrol, LIFIBROL

Patent coverage: 156 distinct patent families (582 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

0 indications (0 at ChEMBL trial phase 4).

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE3	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT01057654	PHASE3	COMPLETED	A Study Comparing the Mechanisms of Action of Lifibrol and Pravastatin

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).